11 Paid Clinical Research Studies in Newport Beach, California

A Study Assessing KB304 for the Treatment of Wrinkles in Women

The aim of this study is to investigate the safety and efficacy of KB304, an investigational gene therapy to correct moderate to severe wrinkles in the décolleté region (V-shaped c

📍 Steve Yoelin Medical Associates — Newport Beach, California

💵 The study is a randomized double-blind study and participants will receive either KB304 (active group) or placebo (inact

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphod

📍 Hoag Hospital Newport Beach — Newport Beach, California

💵 Subjects will receive a 3-day LD chemotherapy regimen with fludarabine and cyclophosphamide, administered according to i

Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio

📍 University of California, Irvine Medical Center — Newport Beach, California

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify,

📍 Hoag Family Cancer Institute — Newport Beach, California

💵 Participants will undergo a research 61Cu-NU101 PET/CT, as follows: Each subject will receive a single administration of

A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants

Single center, double-masked study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Subjects

📍 Site 101 — Newport Beach, California

Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes

📍 HOAG memorial hospital presbyterian — Newport Beach, California

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor rec

📍 Patty & George Hoag Cancer Center — Newport Beach, California

💵 The study participants will receive one of the study treatments: * Sevabertinib as a tablet taken by mouth twice a day

Secretome Treatment for Facial Rejuvenation

Secretome treatment for facial rejuvenation

📍 Steve Yoelin, MD — Newport Beach, California

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen thera

📍 Hoag Memorial Hospital Presbyterian — Newport Beach, California

💵 All patients will receive supportive care according to the SOC for the trial site hospital likely to include remdesivir

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average le

📍 USC Newport Beach — Newport Beach, California

💵 In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymp

📍 Hoag Memorial Hospital — Newport Beach, California

💵 Following a second 1-week rest period, subjects will receive up to 4 repeated 4 week cycles of CD19 t haNK in combinatio